v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Operating Expenses:        
Research and development $ 165,577 $ 62,133 $ 1,774,166 $ 1,824,591
General and administrative 978,576 788,325 3,640,777 745,294
Total Operating Expenses 1,144,153 850,458 5,414,943 2,569,885
Loss from Operations (1,144,153) (850,458) (5,414,943) (2,569,885)
Other Expense (Income):        
Interest expense 1,943 72,659 72,659 341,048
Loss on change in fair value of derivative liabilities 6,312 6,312 17,087
Gain on extinguishment of debt (326,345) (326,345) 194,537
Total Other Expense (Income), net 1,943 (247,374) (247,374) 552,672
Loss before provision for income taxes (1,146,096) (603,084) (5,167,569) (3,122,557)
Provision for income taxes
Net loss $ (1,146,096) $ (603,084) $ (5,167,569) $ (3,122,557)
Net Loss Per Share        
Basic (in Dollars per share) $ (0.13) $ (0.1) $ (0.66) [1] $ (0.96) [1]
Diluted (in Dollars per share) $ (0.13) $ (0.1) $ (0.66) [1] $ (0.96) [1]
Weighted Average Common Shares Outstanding:        
Basic (in Shares) 8,701,837 5,827,039 7,812,264 [1] 3,249,999 [1]
Diluted (in Shares) 8,701,837 5,827,039 7,812,264 [1] 3,249,999 [1]
[1] The number of shares and per share value of the Company’s common stock have been retroactively recast to reflect the exchange ratio pursuant to the Merger (see Note 3).